Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal ...

Naturally, more work is needed. Although GLS -1 agonists have been used in diabetes for 20 years, some of the newer findings ...

Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) ("Tiziana" or the "Company"), a biotechnology company developing breakthrough immunomodulation therapies with its ...

As GLP-1 RA use soars, experts are worried that patients may not be getting the right nutrients in their diets. How can ...

Hangzhou Sciwind Biosciences Co., a pre-commercial biopharmaceutical company focusing on developing innovative therapies to treat metabolic diseases, today announced a licensing and collaboration ...

A new weight loss biotech launched with $410 million and three assets from China. Roche's Chugai penned a deal to develop ...

Maridebart cafraglutide, a novel injectable GLP-1 receptor agonist/GIP receptor antagonist, reduced body weight by up to ...

New findings on semaglutide and tirzepatide published in 2024 revealed that the medications may have benefits beyond lowering glucose levels and body weight.At the Cardiometabolic Health Congress in ...

Scholar Rock , a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic disorders, and other serious diseases where protein ...

Dignity Health January marks Healthy Weight Awareness Month, and with the new year, many are setting health and weight loss ...

The drug's development was funded by Novo Nordisk, the maker of popular semaglutide drugs like Ozempic and Wegovy. While ...

Independence Blue Cross has instituted an 18-month benefit exclusion on certain drugs that receive accelerated approval from ...